Our results suggest that atorvastatin suppresses the proliferation, motility, invasion, and metastasis of mesenchymal-like NSCLC by inhibiting YAP/TAZ activity, which confer a metastatic phenotype and chemoresistance. The gene discussed is YAP1; the disease is non-small cell lung carcinoma.